Summary:
A pilot clinical trial from the University of Missouri reveals that low-dose rapamycin significantly boosts cerebral blood flow in healthy, middle-aged carriers of the APOE4 gene, the strongest genetic risk factor for late-onset Alzheimer’s disease. Female carriers demonstrated the most pronounced vascular improvements, highlighting the anti-aging compound’s potential as a targeted, precision preventative therapy years before cognitive decline begins.
Key Facts:
- Selective Hemodynamic Boost: Following a four-week regimen of low-dose daily rapamycin, significant increases in cerebral blood flow were detected exclusively in APOE4 carriers, with no equivalent vascular shift observed in non-carrier controls.
- Pronounced Response in Women: Female APOE4 carriers exhibited the greatest gains in cerebral perfusion—a critical outcome given that women account for nearly two-thirds of all diagnosed Alzheimer’s cases.
- Early Preventative Window: The intervention targeted asymptomatic adults aged 45 to 65, establishing that vascular deficits associated with genetic Alzheimer’s risk can be therapeutically modified decades before clinical dementia symptoms appear.
Source: University of Missouri
The apolipoprotein E epsilon 4 (APOE4) allele stands as the most potent known genetic risk factor for developing sporadic, late-onset Alzheimer’s disease. Carrying a single copy triples the lifetime risk, while carrying two copies can increase that risk twelvefold.
Long before extracellular amyloid plaques or neurofibrillary tau tangles materialize, people carrying the APOE4 variant frequently exhibit subtle, insidious physiological defects—most notably, chronic hypoperfusion, or restricted cerebral blood flow to vital memory hubs.
Because healthy neurons depend on steady microvascular perfusion for oxygenation and metabolic clearance, this early vascular shortfall accelerates neural aging and lowers the threshold for neurodegenerative cascades.
Now, a clinical study led by investigators at the University of Missouri (Mizzou) suggests that this early circulatory breakdown is not an unchangeable fate. Published in the Journal of Cerebral Blood Flow & Metabolism, the findings demonstrate that the mTOR-inhibiting drug rapamycin can directly boost cerebral perfusion in cognitively healthy middle-aged APOE4 carriers.
From Preclinical Longevity to Human Precision Medicine
The research was spearheaded by Ai-Ling Lin, Ph.D., a professor in Mizzou’s School of Medicine and College of Arts and Science, and an investigator at the Roy Blunt NextGen Precision Health building.
Prior to joining Mizzou, Dr. Lin’s laboratory performed pioneering animal work showing that rapamycin—an FDA-approved immunosuppressant primarily prescribed to prevent organ transplant rejection and treat rare lung conditions—slows neurological aging and restores cerebral blood flow in transgenic APOE4 mice.
To determine whether these neuroprotective effects translate to human biology, Lin designed a clinical trial involving healthy adults aged 45 to 65 who were genetically screened for APOE4 status. Crucially, none of the participants exhibited clinical memory impairment or dementia symptoms.
Participants received a daily low dose of rapamycin over a four-week trial period. Neuroimaging assessments revealed a striking, genotype-dependent effect: only APOE4 carriers experienced significant gains in cerebral blood flow. Non-carriers taking the same regimen did not exhibit comparable vascular shifts, demonstrating that the drug acts directly upon the specific microvascular vulnerability induced by the variant.
“Alzheimer’s tends to happen more in older people, especially for those with APOE4,” said Dr. Lin. “If we can slow down aging in the brain for those people most at risk, maybe we can reduce the risk of them developing Alzheimer’s disease.”
High-Impact Protection for Women at Risk
The trial revealed another crucial clinical pattern: female APOE4 carriers derived the most dramatic improvements in brain blood flow.
This sexual dimorphism holds major clinical weight. Women represent nearly two-thirds of the global population living with Alzheimer’s disease, and female APOE4 carriers consistently exhibit more rapid cognitive deterioration and neurodegeneration than male counterparts with the same genotype.
“We also found that females with APOE4 saw the greatest improvement in brain blood flow, which is significant given that nearly two-thirds of people with Alzheimer’s are women,” Lin noted. “This research is an example of precision medicine, as we work to identify who can benefit from this drug the most.”
In addition to enhancing cerebral perfusion, the study examined systemic impacts across downstream metabolic, inflammatory, and gut microbiome pathways, suggesting that systemic longevity therapeutics can remodel whole-body physiology to support intracranial health.
Operating out of Mizzou’s Roy Blunt NextGen Precision Health facility, Lin and her colleagues plan to expand these preliminary findings into larger, longitudinal clinical trials. The overarching goal is to determine whether sustained, long-term restoration of cerebral blood flow through targeted anti-aging therapeutics can permanently delay, or even prevent, the clinical onset of Alzheimer’s disease in high-risk populations.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this Alzheimer’s and neuropharmacology Research:
- Media Contact: Brian Consiglio
- Source: University of Missouri-Columbia
- Image Credit: Image credited to Neuroscience News
- Original Research is Open Access: Journal of Cerebral Blood Flow & Metabolism (Sept 22, 2026). “Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: a pilot single-arm trial.” Authors: Chetan Aware, Caitlin Maria Neher, Carter Woods, Oleksandr Khegai, Alok Kumar Dwivedi, Maalavika Govindarajan, Kira Ivanich, Mehmet Kurt, David Beversdorf, Jianlin Cheng, Nathan Bresette, Taixing Cui, Priti Balchandani, Mitzi M. Gonzales, Aaron C. Ericsson, Talissa Altes, and Ai-Ling Lin.
- DOI: 10.1177/0271678X261490342
Abstract
Rapamycin increases cerebral blood flow and modulates metabolic, inflammatory, and microbiome profiles in healthy middle-aged APOE4 carriers: a pilot single-arm trial
Carriers of the apolipoprotein E4 (APOE4) allele often develop cerebrovascular dysfunction and broader systemic alterations decades before the onset of Alzheimer’s disease (AD) pathology or clinical symptoms. Early interventions that can improve these functions may help delay or slow AD progression.
In this study, we repurposed rapamycin (sirolimus), an FDA-approved medication with anti-aging properties, to target APOE4 associated multisystem dysfunction. We conducted a single arm trial of low dose rapamycin (1 mg/day for 4 weeks) in cognitively normal adults aged 45 to 65 years, prior to detectable AD pathology, stratified by APOE genotype.
The primary outcome was cerebral blood flow (CBF), while secondary outcomes included plasma metabolomics, inflammatory cytokines, AD biomarkers, and gut microbiome composition. Twenty-three participants completed the study, including nine APOE4 carriers and fourteen non-carriers.
Rapamycin significantly increased CBF in APOE4 carriers, with increases exceeding 15% across multiple brain regions, and improved metabolic and inflammatory profiles with minimal adverse effects. In contrast, non-carriers showed no significant change in CBF and exhibited distinct physiological responses, highlighting genotype dependent effects.
These findings suggest that rapamycin may mitigate early cerebrovascular and systemic dysfunction in APOE4 carriers and support a precision medicine approach in which therapeutic response is influenced by genotype.
